Table 4.
Structural Components of ADCS Associated with and Unassociated with Ocular Adverse Events
| ADC | MAb mode | Target | Cytotoxin | Linker | |
|---|---|---|---|---|---|
| ADCs associated with ocular AEs | Trastuzumab emtansine (Kadcyla®, T-DM1) | Humanized | Her-2 | Maytansine (DM1) | SMCC |
| Lorvotuzumab mertansine (IMGN-901) | Humanized | CD56 | Maytansine (DM1) | SPP | |
| SAR3419 (HuB4-DM4) | Humanized | CD19 | Maytansine (DM4) | SPDB | |
| BT-062 | Chimerized | CD138 Syndecan1) | Maytansine (DM4) | SPDB | |
| SAR566658 (HuDS6-DM4) | Humanized | Muc1 (CA6) | Maytansine (DM4) | SPDB | |
| SGN-75 | Humanized | CD70 | Auristatin (MMAF) | Maleimidocaproyl (mc) | |
| IMGN242 (huc242-DM4) | Humanized | CanAg | Maytansine (DM4) | SPDB | |
| SGN-CD19A | Humanized | CD19 | Auristatin (MMAF) | Maleimidocaproyl (mc) | |
| AVE9633 | Humanized | CD33 | Maytansine (DM4) | SPDB | |
| GO | Humanized | CD33 | Calicheamicin | Hydrazone | |
| MEDI-547 | Human | EphA2 | Auristatin (MMAF) | Maleimidocaproyl (mc) | |
| IMGN 853 | Humanized | FRa | Maytansine (DM4) | SPDB | |
| AGS-16M8F (AGS-6MF) | Fully human | ENPP3 | Auristatin (MMAF) | Maleimidocaproyl (mc) | |
| ADCs unassociated with ocular AEsa | Brentuximab vedotin (Adcetris®, SGN-35) | Chimeric | CD30 | Auristatin (MMAE) | vc |
| Inotuzumab ozogamicin (CMC-544) | Humanized | CD22 | Calicheamicin | Hydrazone/AcBut | |
| Glembatumumab vedotin (CDX-011, CR-011-vcMMAE) | Fully human | GPNMB | Auristatin (MMAE) | vc | |
| Milatuzumab–doxorubicin (IMMU-110) | Humanized | CD74 | Doxorubicin | Hydrazone | |
| AGS-22M6E (ASG-22ME) | Fully human | Nectin-4 | Auristatin (MMAE) | vc | |
| AMG-172 | ND | ND | ND | ND | |
| AMG-595 | Fully human | EGFRvIII | Maytansinoid | Noncleavable | |
| ASG-5ME (AGS-5M2E) | Fully human | SLC44A4 | Auristatin (MMAE) | vc | |
| DEDN-6526A | Humanized | ET8R (endothelin B) | Auristatin (MMAE) | vc | |
| IMGN 529 (K7153A-SMCC-DM1) | Humanized | CD37 | Maytansine (DM1) | SMCC | |
| IMMU-130 (hMN14-SN38) | Humanized | CEACAM5 | SN-38 | CL2 | |
| MDX-1203 | Fully human | CD70 | MGBA | vc | |
| PSMA-ADC (PSMA-ADC-1301) | Fully human | PSMA | Auristatin (MMAE) | vc | |
| RG-7450 (DSTP-3086S) | ND | ND | Auristatin | ND | |
| RG-7458 | ND | MUC16 (CA125) | Auristatin (MMAE) | ND | |
| RG-7593 (pinatuzumab vedotin, DCDT-2980S) | Humanized | CD22 | Auristatin (MMAE) | vc | |
| RG-7596 (DCDS-4501A) | Humanized | CD79b | Auristatin | ND | |
| RG-7598 | ND | ND | Auristatin | ND | |
| RG-7599 | ND | MUC16 (CA125) | Auristatin | ND | |
| RG-7600 | ND | ND | Auristatin | ND | |
| BAY 94–9343 | Fully human | Mesothelin | Maytansine (DM4) | SPDB |
a
Modified from Sassoon and Blanc.112
EGFR, epidermal growth factor receptor; MMAE, monomethyl auristatin E; ND, nondisclosed.